Is OCREVUS right for me?
OCREVUS is not suitable for everyone, so it is important that you discuss with your doctor or nurse whether this medicine is right for you.
Do not use OCREVUS if:
You have had an allergic reaction to OCREVUS or any of its ingredients.
Before you receive OCREVUS, tell your doctor if:
- You have an infection, or a history of recurring or long-term infection (such as hepatitis B)
- You are taking, or have previously taken, medicines which may affect your immune system (such as other medicines for MS)
- You have had, or intend to have, any immunisation with a vaccine.
- You are allergic to any other medicines or any other substances such as foods, preservatives or dye.
- You are pregnant, or intend to become pregnant.
- You are breastfeeding, or plan to breastfeed.
- For more information click here
Is OCREVUS available for patients with Multiple Sclerosis (MS) in New Zealand?
OCREVUS is funded for PwRMS from December 1st 2019 for those who meet pre-defined criteria.
OCREVUS is not PHARMAC funded for PwPPMS. If you would like more information please contact Roche Products phone 0800 656 464
OCREVUS helps with signs and symptoms of Relapsing-Remitting Multiple Sclerosis (RRMS)
When a relapse occurs, symptoms may be experienced suddenly, within a few hours, or slowly develop over a few days. As MS progresses, the damage caused by relapses may grow and could lead to permanent disability.
In people with RRMS there are periods of full recovery (in which symptoms disappear completely) or partial recovery (in which some symptoms remain).
OCREVUS decreases the number of relapses, and slows the worsening of RRMS compared to beta-interon (another medication for MS).
OCREVUS only needs to given every six months after the first dose, leaving you to get on with life in between treatments.
OCREVUS has shown promising results so far in reducing the frequency of MS relapses and slowing the overall progression of the disease.
Reduce the number of relapses by about half
OCREVUS helps with signs and symptoms of Primary Progressive Multiple Sclerosis (PPMS)
PPMS advances more steadily than RRMS.
OCREVUS slows the worsening of PPMS
OCREVUS only needs to be given every six months after the first dose, leaving you to get on with life between treatments
OCREVUS has shown promising results so far in slowing the overall progression of the disease.
Reduce the progression of disability by about one quarter